Your browser doesn't support javascript.
Molnupiravir provides little benefit in vaccinated adults with COVID-19.
Drug Ther Bull ; 61(6): 84, 2023 Jun.
Article in English | MEDLINE | ID: covidwho-2291322
ABSTRACT
Overview of Butler CC, Hobbs FDR, Gbinigie OA, et al Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC) an open-label, platform-adaptive randomised controlled trial. Lancet 2023;401281-93.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Humans Language: English Journal: Drug Ther Bull Year: 2023 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Adult / Humans Language: English Journal: Drug Ther Bull Year: 2023 Document Type: Article